Navigation Links
Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences
Date:5/4/2010

RICHMOND, Calif., May 4 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic™ development programs and an overview of the company's business strategy at two investor conferences during the month of May:

  • The Ninth Annual JMP Securities Research Conference in San Francisco, at 2:00 pm PT on Monday, May 10.
  • The Bank of America Merrill Lynch Health Care Conference in New York City, at 4:20 pm ET on Wednesday, May 12.

Live webcasts of the presentations will be available on the Sangamo BioSciences website in the Investor Relations section http://investor.sangamo.com/index.cfm under Events and Presentations. A replay of each presentation will be archived on the Sangamo website for two weeks after the event.

About Sangamo

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification.  The most advanced ZFP Therapeutic™ development program is currently in a Phase 2b clinical trial for evaluation of safety and clinical effect in patients with diabetic neuropathy and a Phase 2 trial in ALS. Sangamo also has two Phase 1 clinical trials to evaluate safety and clinical effect of a treatment for HIV/AIDS and another Phase 1 trial to evaluate safety and clinical effect of a treatment for recurrent glioblastoma multiforme. Other therapeutic development programs are focused on neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases.  Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs).  By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell function.  Sangamo is also developing sequence-specific ZFP Nucleases (ZFNs) for gene modification.  Sangamo has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the company's web site at http://www.sangamo.com/.


'/>"/>
SOURCE Sangamo BioSciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Sangamo BioSciences Announces Presentation at Cowen and Company Health Care Conference
2. Sangamo BioSciences Reports Fourth Quarter and Full Year 2009 Financial Results
3. Sangamo BioSciences Announces Presentation at BIO CEO & Investor Conference
4. Sangamo BioSciences Provides Update on Phase 1 Safety Trial of SB-728-T for HIV/AIDS
5. Sangamo BioSciences Announces Presentation at Merriman Curhan Fords Investor Summit 2009
6. Sangamo BioSciences Announces Third Quarter 2009 Conference Call and Webcast
7. Sangamo Announces Pricing of Public Offering of Common Stock
8. Sigma-Aldrich(R) and Sangamo BioSciences Announce Major Expansion of ZFP Technology License Agreement
9. Sangamo BioSciences Announces Presentation at the UBS Global Life Sciences Conference
10. Sangamos Zinc Finger Nuclease Technology Used to Efficiently Modify Human Stem Cells
11. Sangamo BioSciences Reports Second Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... ... April 28, 2017 , ... ... has validated a 0.2 ng/mL lower limit (LLOQ) assay for nicotine and two ... LLOQ assay, the ultra-low trace nicotine assay meets additional needs of tobacco industry ...
(Date:4/27/2017)... ... 2017 , ... Oncolinx, a spin-out of the Center for ... taken their cancer research out of this world. On April 22, 2017, an ... the International Space Station’s (ISS) U.S. National Laboratory, managed by the Center for ...
(Date:4/27/2017)... ... , ... Mitotech S.A, a Luxembourg based clinical stage biotechnology company, announced positive ... a rare devastating genetic disease that leads to a sudden and rapid loss of ... patients carrying 11778, 14484 and 3460 mutations and having experienced the onset of symptoms ...
(Date:4/27/2017)... ... April 27, 2017 , ... Arrowhead ... ( http://www.paintherapeuticsummit.com ) is coming to San Diego, CA on September 27-28, 2017. ... learn about the latest advances in the treatment of various types of pain. ...
Breaking Biology Technology:
(Date:4/13/2017)... MONICA, Calif. , April 13, 2017 ... New York will feature emerging and evolving ... Summits. Both Innovation Summits will run alongside the expo ... of speaker sessions, panels and demonstrations focused on trending ... coast,s largest advanced design and manufacturing event will take ...
(Date:4/11/2017)... 2017 NXT-ID, Inc. (NASDAQ:   NXTD ... the appointment of independent Directors Mr. Robin D. Richards ... of Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief ... to their guidance and benefiting from their considerable expertise as ...
(Date:4/4/2017)... YORK , April 4, 2017   EyeLock ... today announced that the United States Patent and Trademark ... patent broadly covers the linking of an iris image ... same transaction) and represents the company,s 45 th ... latest patent is very timely given the multi-modal biometric ...
Breaking Biology News(10 mins):